tiprankstipranks
Nurix Therapeutics, Inc. (NRIX)
NASDAQ:NRIX
US Market
NRIX
Nurix Therapeutics
RESEARCH TOOLSreports
Want to see NRIX full AI Analyst Report?

Nurix Therapeutics (NRIX) Stock Forecast & Price Target

587 Followers
See the Price Targets and Ratings of:

NRIX Analyst Ratings

Strong Buy
12Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Nurix
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NRIX Stock 12 Month Forecast

Average Price Target

$33.00
▲(88.46% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Nurix Therapeutics in the last 3 months. The average price target is $33.00 with a high forecast of $45.00 and a low forecast of $25.00. The average price target represents a 88.46% change from the last price of $17.51.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","27":"$27","46":"$46","17.5":"$17.5","36.5":"$36.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,17.5,27,36.5,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.39,19.513846153846153,21.63769230769231,23.761538461538464,25.885384615384616,28.00923076923077,30.133076923076924,32.25692307692308,34.38076923076923,36.504615384615384,38.628461538461536,40.752307692307696,42.87615384615385,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.39,18.590769230769233,19.79153846153846,20.992307692307694,22.193076923076923,23.393846153846155,24.594615384615388,25.795384615384616,26.996153846153845,28.196923076923078,29.39769230769231,30.59846153846154,31.79923076923077,{"y":33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.39,17.975384615384616,18.560769230769232,19.146153846153847,19.731538461538463,20.31692307692308,20.902307692307694,21.487692307692306,22.073076923076925,22.658461538461538,23.243846153846157,23.82923076923077,24.414615384615384,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.97,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.81,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.48,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.81,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.39,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$45.00Average Price Target$33.00Lowest Price Target$25.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on NRIX
Gil Blum
Needham
Needham
$34
Buy
94.17%
Upside
Reiterated
06/15/26
Nurix Maintained at Buy as Bexobrutideg Data Underscore Safety Edge; $34 Price Target Reaffirmed
Stifel Nicolaus Analyst forecast on NRIX
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$34
Buy
94.17%
Upside
Reiterated
06/15/26
Stifel Nicolaus Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)
Jefferies Analyst forecast on NRIX
Roger Song
Jefferies
Jefferies
$45
Buy
157.00%
Upside
Reiterated
06/15/26
Jefferies Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
H.C. Wainwright Analyst forecast on NRIX
Robert Burns
H.C. Wainwright
H.C. Wainwright
$32
Buy
82.75%
Upside
Reiterated
06/11/26
Analysts Are Bullish on Top Healthcare Stocks: Centene (CNC), Henry Schein (HSIC)
J.P. Morgan Analyst forecast on NRIX
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
BTIG Analyst forecast on NRIX
Jeet Mukherjee
BTIG
BTIG
$32
Buy
82.75%
Upside
Reiterated
06/11/26
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), Nurix Therapeutics (NASDAQ: NRIX) and Gilead Sciences (NASDAQ: GILD)
Wells Fargo Analyst forecast on NRIX
Derek Archila
Wells Fargo
Wells Fargo
$28→$25
Hold
42.78%
Upside
Downgraded
06/09/26
Nurix Therapeutics downgraded to Equal Weight from Overweight at Wells FargoNurix Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
Truist Financial Analyst forecast on NRIX
Gregory Renza
Truist Financial
Truist Financial
$30→$32
Buy
82.75%
Upside
Reiterated
06/09/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Incyte (NASDAQ: INCY)
Morgan Stanley Analyst forecast on NRIX
Terence Flynn
Morgan Stanley
Morgan Stanley
$15→$36
Buy
105.60%
Upside
Reiterated
06/08/26
Morgan Stanley’s Terence Flynn Reiterates Buy on Nurix, Citing Value-Creating Roche Partnership and Long‑Term Bexobrutideg Growth Potential
Piper Sandler Analyst forecast on NRIX
Biren Amin
Piper Sandler
Piper Sandler
$35
Buy
99.89%
Upside
Reiterated
05/13/26
Piper Sandler Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
Oppenheimer Analyst forecast on NRIX
Matthew Biegler
Oppenheimer
Oppenheimer
$28
Buy
59.91%
Upside
Reiterated
05/13/26
Nurix Therapeutics (NRIX) Receives a Buy from Oppenheimer
RBC Capital Analyst forecast on NRIX
Brian Abrahams
RBC Capital
RBC Capital
$30
Buy
71.33%
Upside
Reiterated
04/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Staar Surgical (NASDAQ: STAA) and Nurix Therapeutics (NASDAQ: NRIX)
Mizuho Securities Analyst forecast on NRIX
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
$30
Buy
71.33%
Upside
Reiterated
01/29/26
Nurix Therapeutics (NRIX) Receives a Buy from Mizuho Securities
UBS Analyst forecast on NRIX
David Dai
UBS
UBS
$26→$23
Buy
31.35%
Upside
Reiterated
11/10/25
Analysts Offer Insights on Healthcare Companies: Catalyst Pharma (NASDAQ: CPRX), Rapid Micro Biosystems (NASDAQ: RPID) and Nurix Therapeutics (NASDAQ: NRIX)
Barclays Analyst forecast on NRIX
Peter Lawson
Barclays
Barclays
$31
Buy
77.04%
Upside
Reiterated
10/23/25
Barclays Remains a Buy on Nurix Therapeutics (NRIX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on NRIX
Gil Blum
Needham
Needham
$34
Buy
94.17%
Upside
Reiterated
06/15/26
Nurix Maintained at Buy as Bexobrutideg Data Underscore Safety Edge; $34 Price Target Reaffirmed
Stifel Nicolaus Analyst forecast on NRIX
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$34
Buy
94.17%
Upside
Reiterated
06/15/26
Stifel Nicolaus Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)
Jefferies Analyst forecast on NRIX
Roger Song
Jefferies
Jefferies
$45
Buy
157.00%
Upside
Reiterated
06/15/26
Jefferies Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
H.C. Wainwright Analyst forecast on NRIX
Robert Burns
H.C. Wainwright
H.C. Wainwright
$32
Buy
82.75%
Upside
Reiterated
06/11/26
Analysts Are Bullish on Top Healthcare Stocks: Centene (CNC), Henry Schein (HSIC)
J.P. Morgan Analyst forecast on NRIX
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
BTIG Analyst forecast on NRIX
Jeet Mukherjee
BTIG
BTIG
$32
Buy
82.75%
Upside
Reiterated
06/11/26
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), Nurix Therapeutics (NASDAQ: NRIX) and Gilead Sciences (NASDAQ: GILD)
Wells Fargo Analyst forecast on NRIX
Derek Archila
Wells Fargo
Wells Fargo
$28→$25
Hold
42.78%
Upside
Downgraded
06/09/26
Nurix Therapeutics downgraded to Equal Weight from Overweight at Wells FargoNurix Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
Truist Financial Analyst forecast on NRIX
Gregory Renza
Truist Financial
Truist Financial
$30→$32
Buy
82.75%
Upside
Reiterated
06/09/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Incyte (NASDAQ: INCY)
Morgan Stanley Analyst forecast on NRIX
Terence Flynn
Morgan Stanley
Morgan Stanley
$15→$36
Buy
105.60%
Upside
Reiterated
06/08/26
Morgan Stanley’s Terence Flynn Reiterates Buy on Nurix, Citing Value-Creating Roche Partnership and Long‑Term Bexobrutideg Growth Potential
Piper Sandler Analyst forecast on NRIX
Biren Amin
Piper Sandler
Piper Sandler
$35
Buy
99.89%
Upside
Reiterated
05/13/26
Piper Sandler Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
Oppenheimer Analyst forecast on NRIX
Matthew Biegler
Oppenheimer
Oppenheimer
$28
Buy
59.91%
Upside
Reiterated
05/13/26
Nurix Therapeutics (NRIX) Receives a Buy from Oppenheimer
RBC Capital Analyst forecast on NRIX
Brian Abrahams
RBC Capital
RBC Capital
$30
Buy
71.33%
Upside
Reiterated
04/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Staar Surgical (NASDAQ: STAA) and Nurix Therapeutics (NASDAQ: NRIX)
Mizuho Securities Analyst forecast on NRIX
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
$30
Buy
71.33%
Upside
Reiterated
01/29/26
Nurix Therapeutics (NRIX) Receives a Buy from Mizuho Securities
UBS Analyst forecast on NRIX
David Dai
UBS
UBS
$26→$23
Buy
31.35%
Upside
Reiterated
11/10/25
Analysts Offer Insights on Healthcare Companies: Catalyst Pharma (NASDAQ: CPRX), Rapid Micro Biosystems (NASDAQ: RPID) and Nurix Therapeutics (NASDAQ: NRIX)
Barclays Analyst forecast on NRIX
Peter Lawson
Barclays
Barclays
$31
Buy
77.04%
Upside
Reiterated
10/23/25
Barclays Remains a Buy on Nurix Therapeutics (NRIX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nurix Therapeutics

3 Months
Robert BurnsH.C. Wainwright
Success Rate
9/16 ratings generated profit
56%
Average Return
+13.04%
Copying Robert Burns's trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +13.04% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
11/16 ratings generated profit
69%
Average Return
+51.00%
Copying Robert Burns's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +51.00% per trade.
2 Years
Peter LawsonBarclays
Success Rate
12/16 ratings generated profit
75%
Average Return
+37.97%
Copying Peter Lawson's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +37.97% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NRIX Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
19
14
13
17
25
Buy
6
3
0
1
3
Hold
1
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
17
13
18
29
In the current month, NRIX has received 28 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. NRIX average Analyst price target in the past 3 months is 33.00.
Each month's total comprises the sum of three months' worth of ratings.

NRIX Financial Forecast

NRIX Earnings Forecast

Next quarter’s earnings estimate for NRIX is -$0.72 with a range of -$0.86 to -$0.45. The previous quarter’s EPS was -$0.79. NRIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NRIX has Performed in-line its overall industry.
Next quarter’s earnings estimate for NRIX is -$0.72 with a range of -$0.86 to -$0.45. The previous quarter’s EPS was -$0.79. NRIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NRIX has Performed in-line its overall industry.

NRIX Sales Forecast

Next quarter’s sales forecast for NRIX is $15.29M with a range of $2.75M to $40.00M. The previous quarter’s sales results were $6.25M. NRIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NRIX has Performed in-line its overall industry.
Next quarter’s sales forecast for NRIX is $15.29M with a range of $2.75M to $40.00M. The previous quarter’s sales results were $6.25M. NRIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NRIX has Performed in-line its overall industry.

NRIX Stock Forecast FAQ

What is NRIX’s average 12-month price target, according to analysts?
Based on analyst ratings, Nurix Therapeutics, Inc.’s 12-month average price target is 33.00.
    What is NRIX’s upside potential, based on the analysts’ average price target?
    Nurix Therapeutics, Inc. has 88.46% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NRIX a Buy, Sell or Hold?
          Nurix Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Nurix Therapeutics, Inc.’s price target?
            The average price target for Nurix Therapeutics, Inc. is 33.00. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $45.00 ,the lowest forecast is $25.00. The average price target represents 88.46% Increase from the current price of $17.51.
              What do analysts say about Nurix Therapeutics, Inc.?
              Nurix Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of NRIX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.